Precision Biosciences (DTIL) Non Operating Investment Income (2021 - 2026)
Precision Biosciences (DTIL) posted quarterly Non Operating Investment Income of -$3.0 million for Q1 2026, down 6122.45% year-over-year from $49000.0 in Q1 2025, and down 1089.92% quarter-over-quarter from -$248000.0 in Q4 2025.
Precision Biosciences (DTIL) Non Operating Investment Income (2021 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Non Operating Investment Income for 6 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income fell 6122.45% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at -$5.7 million (down 965.04% YoY), while the FY2025 annual figure was -$2.7 million, down 1133.33% from the prior year.
- Non Operating Investment Income fell to -$3.0 million in Q1 2026 per DTIL's latest filing, from -$248000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.6 million in Q4 2023 and bottomed at -$3.0 million in Q1 2026.
- Historically, Non Operating Investment Income has averaged -$363384.6 across 5 years, with a median of -$248000.0 in 2025.
- Annual changes were most pronounced in 2023 — Non Operating Investment Income soared 414.31% — and 2026, when it tumbled 6122.45%.
- Precision Biosciences' Non Operating Investment Income stood at -$510000.0 in 2022, then jumped by 414.31% to $1.6 million in 2023, then tumbled by 141.11% to -$659000.0 in 2024, then jumped by 62.37% to -$248000.0 in 2025, then tumbled by 1089.92% to -$3.0 million in 2026.
- Business Quant data shows DTIL's Non Operating Investment Income at -$3.0 million in Q1 2026, -$248000.0 in Q4 2025, and -$3000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | -244,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -244,000.00 |
| Jun 30, 2026 | -244,000.00 |
| Mar 31, 2026 | -2.95 Mn |
| Mar 31, 2026 | -2.95 Mn |
| Dec 31, 2025 | -248,000.00 |
| Dec 31, 2025 | -248,000.00 |
| Sep 30, 2025 | -3,000.00 |
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -2.46 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | 49,000.00 |
| Mar 31, 2025 | 49,000.00 |
| Dec 31, 2024 | -659,000.00 |
| Dec 31, 2024 | -659,000.00 |
| Sep 30, 2024 | 571,000.00 |
| Sep 30, 2024 | 571,000.00 |
| Jun 30, 2024 | 694,000.00 |
| Jun 30, 2024 | 694,000.00 |
| Mar 31, 2024 | -348,000.00 |
| Mar 31, 2024 | -348,000.00 |